The in vitro activities of three new quinolones (sparfloxacin, and PD 131,628) were compared with that of ciprofloxacin against 5,252 routine clinical aerobic and facultatively anaerobic bacterial isolates. Overall, CI-960 was the most active drug in vitro (MIC for 90% of the strains tested, 0.13 ,ug/ml); ciprofloxacin and sparfloxacin were the least active (MIC for 90% of the strains tested, 1.0 ,ug/ml). All three new quinolones, but particularly CI-960 and PD 131,628, exhibited significantly greater activity than ciprofloxacin against enterococci and staphylococci. 
The recent resurgence of clinical use of quinolones in the treatment of bacterial infections is due to the development of the new fluorinated compounds which exhibit both greater potency and broader spectra of antibacterial activity. De (Table 1) . Susceptibility data for these four quinolones determined with 5,252 bacterial isolates are summarized in Table 2 .
Members of the family Enterobacteriaceae were highly susceptible to all four drugs. Against this family of bacteria, CI-960 and PD 131,628 were most active, with an MIC for 90% of the organisms tested (MIC90) of 0.03 ,ug/ml, compared with 0.06 and 0.25 p.g/ml for ciprofloxacin and sparfloxacin, respectively. For all of the drugs, the highest MIC90s occurred with Serratia marcescens and Providencia rettgeri, but only the MIC90 of sparfloxacin was >1.0 ,ug/ml. All four quinolones showed good activity against nonen- Staphylococcus epidermidis and Staphylococcus haemolyticus, and for S. haemolyticus the MIC50s of these three drugs were also >2.0 Fg/ml. But all isolates of these two species were susceptible to .1.0 ,ug of CI-960 per ml. Other staphylococcal species were susceptible to all four drugs, but ciprofloxacin MICs were generally higher than those of the other compounds.
These four quinolone compounds exhibit potent broadspectrum antibacterial activities against routine clinical bacterial isolates which grow aerobically. The relative activities, expressed as MIC90s for all 5, 252 bacterial isolates combined, were as follows: CI-960 (MIC' , 0.13 ,ug/ml) > PD 131,680 (MIC90, 0.5 pLg/ml) > sparfloxacin = ciprofloxacin (MIC90s, 1.0 Fig/ml) . The percentages of the 5,252 isolates inhibited by 1.0 Lg of drug per ml were 98.9, 95.7, 93.6, and 91.8%, respectively. Although the proportions of susceptible and resistant strains within some species (e.g., S. aureus) varied substantially between different institutions in the study, the relative activities of the four test drugs were the same in each institution. Because of their in vitro activities, these new quinolone agents merit further study.
